Conventional chemotherapy in multiple myeloma.
Multiple myeloma is a disease, mainly affecting elderly individuals, for which no curative therapy is available today. The most important aim of the treatment given to such patients should therefore be to improve the quality of life and prolong the period of non-progressive disease. A concise review is given of the therapeutic options in patients, for whom high-dose cytostatic therapy with stem cell support is not an alternative. Traditional intermittent courses of melphalan and prednisone still holds its role as standard induction therapy. This regimen has convincingly in a recent large world-wide overview been shown to be able to induce a length of overall and progression-free survival, that is comparable to what can be achieved with different forms of combination chemotherapy. For patients refractory to alkylating agents a combination of vincristine, doxorubicin and prednisone (VAD) or intermittent courses of high-dose steroids alone are well proven alternatives. Several new drugs are under evaluation, but their therapeutic role is not yet established.
Westin
J
J
Department of Medicine (Division of Hematology), University of Lund, Sweden.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D018579:Patient Selection; D012074:Remission Induction